Matthew T. Burger

Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor

Sauveur-Michel Maira, Sabina Pecchi, Alan Huang et al. · Molecular Cancer Therapeutics · 2011 · 529 citations

Pharmacy, Medicinal Chemistry, Pharmacology +13

Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer

Matthew T. Burger, Sabina Pecchi, Allan S. Wagman et al. · ACS Medicinal Chemistry Letters · 2011 · 251 citations · Full text

Pharmacy, Oncology, Pharmacology +13

Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic Cancers

Pablo D. García, John L. Langowski, Yingyun Wang et al. · Clinical Cancer Research · 2014 · 111 citations · Full text

Medicine, Oncology, Pharmacology +17

Enantioselective Recognition by a New Chiral Stationary Phase at the Receptor Level

Francesco Gasparrini, Domenico Misiti, Claudio Villani et al. · The Journal of Organic Chemistry · 1995 · 84 citations

Pharmacy, Chemistry, Drug Discovery +13

Identification of <i>N</i>-(4-((1<i>R</i>,3<i>S</i>,5<i>S</i>)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies

Matthew T. Burger, Gisele Nishiguchi, Wooseok Han et al. · Journal of Medicinal Chemistry · 2015 · 76 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13